Glial Mechanisms of Neuropathic Pain and Emerging Interventions.
- Author:
Daehyun JO
1
;
C Richard CHAPMAN
;
Alan R LIGHT
Author Information
- Publication Type:Review
- Keywords: astrocytes; mechanisms; microglia; neuropathic pain; therapeutic strategies
- MeSH: Astrocytes; Carisoprodol; Central Nervous System; Chronic Pain; Cytokines; Ganglia, Spinal; Gap Junctions; Genetic Therapy; Microglia; Neuralgia; Neuroglia; Neurons; Synapses
- From:The Korean Journal of Pain 2009;22(1):1-15
- CountryRepublic of Korea
- Language:English
- Abstract: Neuropathic pain is often refractory to intervention because of the complex etiology and an incomplete understanding of the mechanisms behind this type of pain. Glial cells, specifically microglia and astrocytes, are powerful modulators of pain and new targets of drug development for neuropathic pain. Glial activation could be the driving force behind chronic pain, maintaining the noxious signal transmission even after the original injury has healed. Glia express chemokine, purinergic, toll-like, glutaminergic and other receptors that enable them to respond to neural signals, and they can modulate neuronal synaptic function and neuronal excitability. Nerve injury upregulates multiple receptors in spinal microglia and astrocytes. Microglia influence neuronal communication by producing inflammatory products at the synapse, as do astrocytes because they completely encapsulate synapses and are in close contact with neuronal somas through gap junctions. Glia are the main source of inflammatory mediators in the central nervous system. New therapeutic strategies for neuropathic pain are emerging such as targeting the glial cells, novel pharmacologic approaches and gene therapy. Drugs targeting microglia and astrocytes, cytokine production, and neural structures including dorsal root ganglion are now under study, as is gene therapy. Isoform-specific inhibition will minimize the side effects produced by blocking all glia with a general inhibitor. Enhancing the anti-inflammatory cytokines could prove more beneficial than administering proinflammatory cytokine antagonists that block glial activation systemically. Research on therapeutic gene transfer to the central nervous system is underway, although obstacles prevent immediate clinical application.
